Abstract
The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
Keywords:
checkpoint blockade; immunotherapy; infection; melanoma.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
MeSH terms
-
Adolescent
-
Adrenal Cortex Hormones / adverse effects*
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Cell Cycle Checkpoints
-
Child
-
Child, Preschool
-
Female
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use*
-
Immunotherapy / adverse effects
-
Infections / epidemiology*
-
Infections / etiology
-
Infections / microbiology
-
Infections / virology
-
Infliximab / adverse effects*
-
Infliximab / therapeutic use
-
Male
-
Medical Records
-
Melanoma / complications*
-
Melanoma / drug therapy*
-
Melanoma / microbiology
-
Middle Aged
-
Retrospective Studies
-
Risk Factors
-
Young Adult
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Immunologic Factors
-
Infliximab